Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros is showing strong financial performance with revenue exceeding expectations and gross product sales reaching $11.1M thanks to successful YARTEMLEA launch, demonstrating high demand and formulary access. The company is also focused on expanding YARTEMLEA adoption and has a strong pipeline, with upcoming catalysts expected such as a regulatory decision from the EMA and continued commercial infrastructure development. Risks to consider include clinical, regulatory, partnership, financial, commercial, legal, and market share factors, but the recent J-code assignment and favorable backdrop suggest positive potential for growth in the TA-TMA market.

Bears say

Omeros is a biotechnology company with a pipeline of promising clinical-stage development programs targeting a range of diseases. However, the company has yet to demonstrate significant revenue from its commercialized product, YARTEMLEA, and its other potential treatments are still in early stages of development. With no immediate catalysts to drive significant financial growth, the company's stock may face challenges in the near term.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.